Alexza Pharmaceuticals Inc (ALXA) financial statements (2020 and earlier)

Company profile

Business Address 2091 STIERLIN COURT
MOUNTAIN VIEW, CA 94043
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 8352623
Cash and cash equivalents 8151718
Short-term investments  209 
Other undisclosed cash, cash equivalents, and short-term investments    5
Restricted cash and investments    5
Receivables  00 
Inventory, net of allowances, customer advances and progress billings  43
Inventory  43 
Advances on inventory purchases 1   
Prepaid expense and other current assets1
Other undisclosed current assets 231(5)
Total current assets: 11423124
Noncurrent Assets
Property, plant and equipment 3141517
Restricted cash and investments  3  
Other noncurrent assets 031
Prepaid expense and other noncurrent assets0
Total noncurrent assets: 4201617
TOTAL ASSETS: 15624741
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 71074
Accounts payable 0242
Accrued liabilities 76  
Employee-related liabilities  332
Debt 4764126
Business combination, contingent consideration, liability 12
Deferred revenue and credits 3233
Other undisclosed current liabilities 0(67)(7)5
Total current liabilities: 58121519
Noncurrent Liabilities
Long-term debt and lease obligation 216411 
Long-term debt, excluding current maturities 2164  
Capital lease obligations   11 
Liabilities, other than long-term debt 738913
Deferred revenue and credits 38913
Other liabilities 21  
Business combination, contingent consideration, liability 229
Total noncurrent liabilities: 281021913
Total liabilities: 861133432
Stockholders' equity
Stockholders' equity attributable to parent (72)(52)(24)3
Common stock 0000
Additional paid in capital 361359350337
Accumulated other comprehensive income (loss)  (0)0 
Accumulated deficit (432)(411)(374)(335)
Total stockholders' equity: (72)(52)(24)3
Other undisclosed liabilities and equity   376
TOTAL LIABILITIES AND EQUITY: 15624741

Income statement (P&L) ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues 56484
Revenue, net 33484
Cost of revenue (21)(16)(11)(0)
Cost of goods and services sold (21)(16)(11) 
Gross profit: (16)(10)374
Operating expenses (24)(27)(35)(33)
Other undisclosed operating income  0  
Operating income (loss): (40)(37)2(29)
Nonoperating income
(Debt Instrument, Convertible, Beneficial Conversion Feature)
  13 
Interest and debt expense (8)(7)(1)(1)
Net income (loss): (48)(44)3(30)
Other undisclosed net income (loss) attributable to parent 277(43)2
Net loss available to common stockholders, diluted: (21)(37)(40)(28)

Comprehensive Income ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net income (loss): (48)(44)3(30)
Other comprehensive loss  (37)(40)(28)
Comprehensive loss: (48)(81)(36)(58)
Other undisclosed comprehensive income, net of tax, attributable to parent 27   
Comprehensive loss, net of tax, attributable to parent: (21)(81)(36)(58)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: